Anne-Laurie Pinto Selected Research

Anne-Laurie Pinto Research Topics

6	Encephalitis (Encephalitis, Rasmussen) 12/2023 - 11/2019
5	Limbic Encephalitis (Paraneoplastic Limbic Encephalitis) 01/2023 - 10/2020
4	Glioma (Gliomas) 01/2022 - 10/2020
3	Neoplasms (Cancer) 12/2023 - 11/2019
2	Autoimmune Diseases of the Nervous System 05/2024 - 01/2021
2	Leukocytosis (Pleocytosis) 05/2024 - 10/2021
2	Cerebellar Diseases (Cerebellar Syndrome) 12/2023 - 12/2020
2	Cerebellar Ataxia (Dysmetria) 01/2022 - 10/2020
2	Ataxia (Dyssynergia) 01/2022 - 01/2021
2	Nervous System Paraneoplastic Syndromes 01/2020 - 11/2019
1	Paraneoplastic Cerebellar Degeneration 12/2023
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/2023
1	Autoimmune limbic encephalitis 01/2023
1	Inflammation (Inflammations) 01/2022
1	Testicular Neoplasms (Testicular Cancer) 01/2021
1	Nervous System Diseases (Neurological Disorders) 01/2021
1	Teratoma (Teratoid Tumor) 01/2021
1	Neurologic Manifestations (Neurological Manifestations) 12/2020
1	Myasthenia Gravis 10/2020
1	Thymoma (Thymic Carcinoma) 10/2020
1	Colorectal Neoplasms (Colorectal Cancer) 10/2020
1	Isaacs Syndrome (Neuromyotonia) 10/2020
1	Mesothelioma 11/2019

10	AntibodiesIBA 05/2024 - 01/2020
6	Proteins (Proteins, Gene)FDA Link 12/2023 - 10/2020
4	Leucine (L-Leucine)FDA Link 01/2022 - 10/2020
2	Immunoglobulin G (IgG)IBA 12/2023 - 12/2020
1	gamma-Aminobutyric Acid (GABA)IBA 05/2024
1	AntigensIBA 12/2023
1	AutoantibodiesIBA 12/2023
1	InterferonsIBA 12/2023
1	Epidermal Growth Factor (EGF)IBA 01/2022
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022
1	adenylate kinase 5IBA 10/2021
1	Oligoclonal BandsIBA 10/2021
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	HLA-DRB1*07 antigenIBA 01/2021
1	N 30IBA 12/2020
1	metabotropic glutamate receptor type 1IBA 12/2020
1	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 12/2020
1	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 10/2020
1	Netrin-1IBA 10/2020
1	pembrolizumabIBA 11/2019
1	NivolumabIBA 11/2019
1	Immune Checkpoint InhibitorsIBA 11/2019
1	IpilimumabIBA 11/2019

2	Immunotherapy 05/2024 - 10/2021
1	Aftercare (After-Treatment) 11/2019